Diavacs, Inc. is a San Diego-based clinical stage biotechnology company developing products to reverse the onset of Type 1 Diabetes.

Type 1 Diabetes affects up to 3 million individuals in the U.S. and costs the healthcare system almost $15 billion annually. Insulin is the only option for most patients, but insulin adminstration requires drastic lifestyle changes and cannot prevent the emergenceĀ of complications. DiaVacs is developing products that could reverse the onset of Type 1 Diabetes with the goal of liberating patients from lifelong insulin dependence.


Comments are closed.